A clinical trial involving ganirelix was updated on September 4, 2026. The study, registered as NCT06280560, is titled "Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation."
According to the listing, the trial's current status is recruiting. No phase designation was provided in the available record.
The study is registered on ClinicalTrials.gov and examines aspects of IVF hormonal therapy in relation to endometrial receptivity and senescent cell accumulation in endometrial tissue. Ganirelix is included among the compounds relevant to this hormonal therapy research context.
No outcome data, efficacy findings, or safety results have been reported as part of this update. The recruiting status indicates that participant enrollment is ongoing rather than completed. Details on trial design, eligibility, or endpoints beyond the title are not included in this update.
Readers interested in the broader context of ganirelix, including its approved regulatory status and general profile, can consult the compound overview for additional background.